 |
|
|
| |
Safety & Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers
|
| |
| |
CROI 2020 March 9
Reported by Jules Levin
Devi SenGupta1, Moti Ramgopal2, Cynthia Brinson3, Edwin DeJesus4, Anthony Mills5, Peter Shalit6, Scott McCallister1, Hiba Graham1, Heena Patel1, Lijie Zhong1, Joseph Hesselgesser1, Brian Doehle1, Susan Guo1, Diana M. Brainard1, Steven G. Deeks7
1Gilead Sciences, Inc., Foster City, CA; 2Midway Immunology and Research Center, Fort Pierce, FL; 3Central Texas Clinical Research, Austin, TX; 4Orlando Immunology Center, Orlando, FL; 5Men’s Health Foundation, West Hollywood, CA; 6Peter Shalit MD and Associates, Seattle, WA; 7University of California San Francisco, San Francisco, CA
|
| |
|
|
|
|
|
